PROLOR Biotech, Inc. (PBTH)

[gym gravity]

one thing that will cause prolor to skyrocket is if the EMEA comes to a decision on SGP's FSH-CTP. SGP finalized the application in january and released data from PhaseII/III work in july.


http://www.datamonitor.com/store/News/emea_validates_schering_ploughs_corifollitropin_alfa?productid=6CF2E7A6-6355-4A91-8CE7-7EAF5A84D7E8



EMEA validates Schering-Plough's corifollitropin alfaSchering-Plough has announced that the European Medicines Agency has validated its marketing authorization application for corifollitropin alfa, the company's experimental, sustained follicle stimulant. This application will follow the centralized procedure.

Corifollitropin alfa is being developed as a potential treatment in controlled ovarian stimulation (COS) for the development of multiple follicles and pregnancy in women participating in an assisted reproductive technology program.

Corifollitropin alfa is designed as a sustained follicle stimulant with the same pharmacodynamic profile as follicle stimulating hormone (FSH), but with a markedly prolonged duration of FSH activity, the company said. Due to its ability to initiate and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose of corifollitropin alfa may replace the first seven injections of FSH preparation in a COS treatment cycle.

If approved, corifollitropin alfa would extend Schering-Plough's fertility portfolio, which also includes Puregon.

http://www.fiercebiotech.com/press-releases/schering-plough-announces-phase-iii-data-sustained-follicle-stimulant-0